CN103118669B - 口服药物治疗方法和组合物 - Google Patents

口服药物治疗方法和组合物 Download PDF

Info

Publication number
CN103118669B
CN103118669B CN201180036488.8A CN201180036488A CN103118669B CN 103118669 B CN103118669 B CN 103118669B CN 201180036488 A CN201180036488 A CN 201180036488A CN 103118669 B CN103118669 B CN 103118669B
Authority
CN
China
Prior art keywords
transfer agent
taurolidine
compositions
carcinoma
methylol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180036488.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103118669A (zh
Inventor
罗尔夫·W·普菲尔曼
彼得·盖斯特利希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geistlich Pharma AG
Original Assignee
Geistlich Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma AG filed Critical Geistlich Pharma AG
Publication of CN103118669A publication Critical patent/CN103118669A/zh
Application granted granted Critical
Publication of CN103118669B publication Critical patent/CN103118669B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180036488.8A 2010-06-01 2011-06-01 口服药物治疗方法和组合物 Active CN103118669B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35018310P 2010-06-01 2010-06-01
US61/350,183 2010-06-01
US37031510P 2010-08-03 2010-08-03
US61/370,315 2010-08-03
PCT/IB2011/001539 WO2011151722A2 (en) 2010-06-01 2011-06-01 Methods and compositions for oral pharmaceutical therapy

Publications (2)

Publication Number Publication Date
CN103118669A CN103118669A (zh) 2013-05-22
CN103118669B true CN103118669B (zh) 2016-01-13

Family

ID=45067142

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180036488.8A Active CN103118669B (zh) 2010-06-01 2011-06-01 口服药物治疗方法和组合物

Country Status (9)

Country Link
US (1) US9028866B2 (https=)
EP (1) EP2575783B1 (https=)
JP (2) JP5926243B2 (https=)
CN (1) CN103118669B (https=)
AU (1) AU2011262308B2 (https=)
BR (1) BR112012030641B8 (https=)
CA (1) CA2801309C (https=)
ES (1) ES2614878T3 (https=)
WO (1) WO2011151722A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2632248C2 (ru) * 2012-05-15 2017-10-03 Филипс Лайтинг Холдинг Б.В. Управление устройствами освещения
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
EP3402527B1 (en) * 2016-01-11 2022-09-28 CorMedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
US20190381058A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Methods and compositions for treating neuroblastoma in a juvenile mammalian body
SI3709979T1 (sl) 2017-11-17 2025-03-31 Evonik Operations Gmbh Postopek za pripravo obložene kapsule s trdo ovojnico
JP2021535163A (ja) * 2018-08-28 2021-12-16 コーメディクス・インコーポレーテッド タウロリジン加水分解産物による神経芽細胞腫治療
CN113226325A (zh) * 2018-08-31 2021-08-06 科医公司 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗
WO2020234833A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Method for treating, preventing, inhibiting or reducing cytokine release
WO2020234829A1 (en) * 2019-05-22 2020-11-26 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh
CN111671758A (zh) * 2020-07-06 2020-09-18 长春迈灵生物工程有限公司 牛磺罗定在制备抗hiv病毒药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637320A (en) * 1990-01-15 1997-06-10 Elan Corporation, Plc Controlled absorption naproxen formulation for once-daily administration
WO1999034805A1 (en) * 1998-01-08 1999-07-15 Ed Geistlich Söhne Ag Für Chemische Industrie Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
US6251896B1 (en) * 1999-03-24 2001-06-26 Carter-Wallace, Inc. Compositions and methods for the management of Crohn's disease
EP1116488A2 (en) * 2000-01-05 2001-07-18 Ed. Geistlich Söhne Ag Für Chemische Industrie Treatment of inflammatory Bowel disease
US6555534B1 (en) * 1998-09-11 2003-04-29 Medpointe Healthcare Inc. Method and compositions for the control or eradication of Helicobacter pylori

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
CA2381425A1 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AU779362B2 (en) * 2000-10-27 2005-01-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
SK287902B6 (sk) * 2001-01-31 2012-03-02 Evonik Rohm Gmbh Multiparticulate drug form and method for the preparation thereof
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
US9138408B2 (en) * 2002-06-21 2015-09-22 L'oreal Use of taurine for treating alopecia
US20060198886A1 (en) * 2005-03-01 2006-09-07 Jenkins Richard B Medicament having coated methenamine combined with acidifier
WO2007069272A2 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
ES2318628T3 (es) * 2006-07-25 2009-05-01 Claus Herdeis Preparacion de formulaciones antimicrobianas que comprenden 7-oxa-2-tia-1,5 diazabiciclo(3.3.1)-nonan-2,2-diona.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637320A (en) * 1990-01-15 1997-06-10 Elan Corporation, Plc Controlled absorption naproxen formulation for once-daily administration
WO1999034805A1 (en) * 1998-01-08 1999-07-15 Ed Geistlich Söhne Ag Für Chemische Industrie Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6555534B1 (en) * 1998-09-11 2003-04-29 Medpointe Healthcare Inc. Method and compositions for the control or eradication of Helicobacter pylori
US6251896B1 (en) * 1999-03-24 2001-06-26 Carter-Wallace, Inc. Compositions and methods for the management of Crohn's disease
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
US6521616B2 (en) * 1999-12-06 2003-02-18 Rhode Island Hospital, A Lifespan Partner Methods of treating tumors with taurolidine
EP1116488A2 (en) * 2000-01-05 2001-07-18 Ed. Geistlich Söhne Ag Für Chemische Industrie Treatment of inflammatory Bowel disease

Also Published As

Publication number Publication date
ES2614878T3 (es) 2017-06-02
BR112012030641A2 (pt) 2016-08-16
US9028866B2 (en) 2015-05-12
BR112012030641B8 (pt) 2022-06-14
CN103118669A (zh) 2013-05-22
JP2016155826A (ja) 2016-09-01
WO2011151722A3 (en) 2012-05-24
US20130089606A1 (en) 2013-04-11
AU2011262308A1 (en) 2013-01-10
CA2801309A1 (en) 2011-12-08
CA2801309C (en) 2018-07-17
WO2011151722A2 (en) 2011-12-08
BR112012030641B1 (pt) 2022-05-24
EP2575783A2 (en) 2013-04-10
AU2011262308B2 (en) 2014-07-31
JP5926243B2 (ja) 2016-05-25
JP2013527224A (ja) 2013-06-27
EP2575783B1 (en) 2017-01-11
HK1183228A1 (zh) 2013-12-20

Similar Documents

Publication Publication Date Title
CN103118669B (zh) 口服药物治疗方法和组合物
US12059397B2 (en) Calcium lactate compositions and methods of use
CN101360495B (zh) 对癌症病人给药mTOR抑制剂
CN102076215A (zh) 5-氟胞嘧啶制剂及其用途
JP6833816B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
CN108295063A (zh) 治疗增殖性疾病的联合疗法(威罗菲尼和mdm2抑制剂)
CN115569197A (zh) Mdm2抑制剂的间歇给药
WO2008016633A2 (en) Combination therapy
TW201924720A (zh) Ｐａｒｐ抑制劑用於治療化療耐藥的卵巢癌或乳腺癌的用途
CN114007599A (zh) 用于局部治疗炎症性肠病的5-氨基乙酰丙酸
EP3791865A1 (en) Active substance delivery system with delayed delivery
US20220233461A1 (en) Active substance delivery system
US20080207644A1 (en) Therapeutic materials and methods
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
JP2022538898A (ja) 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
HK1183228B (en) Methods and compositions for oral pharmaceutical therapy
CN101155600B (zh) 放射线治疗增强剂
JP2703321B2 (ja) 化学療法的抗腫瘍剤と非ステロイド系抗炎症薬による腹腔内治療
HK40092902A (zh) 靶向释放利福昔明组合物
HK1173387A (en) Use of a rapamycin derivative for the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183228

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1183228

Country of ref document: HK